# Molecular Investigation of the Effects of Two Antiepileptic Drugs (Valproic Acid and Levetiracetam) on Alveolar Bone Under Orthodontic Force

**Authors:** Nurhan Bayindir-Durna, Metin Uckan, Seyma Aydin, Selcuk Ozdemir

PMC · DOI: 10.3390/medicina62010178 · 2026-01-15

## TL;DR

This study investigates how two antiepileptic drugs affect alveolar bone during orthodontic force in rats, finding that levetiracetam protects against bone damage.

## Contribution

The study reveals levetiracetam's protective effects on alveolar bone under orthodontic force, contrasting with valproic acid's lack of benefit.

## Key findings

- Levetiracetam reduced oxidative stress, inflammation, and apoptosis in alveolar bone exposed to orthodontic force.
- Levetiracetam restored extracellular matrix balance and limited bone resorption by modulating MMPs and TIMP-1.
- Valproic acid failed to correct molecular alterations and worsened some parameters in orthodontically stressed bone.

## Abstract

Background and Objectives: This study aims to analyze the effects of levetiracetam (LEV) and valproic acid (VPA) administration on oxidative stress, inflammation, apoptosis, extracellular matrix dynamics, and bone remodeling parameters in rat alveolar bone exposed to orthodontic force. Materials and Methods: Four experimental groups were designed for this study: Control, Force, Force + LEV, and Force + VPA. LEV (150 mg/kg/day) or VPA (300 mg/kg/day) was administered intraperitoneally to the experimental groups daily for 6 weeks. At the end of the experimental period, the alveolar bone tissues were used for molecular analyses. RT-PCR analysis was performed to assess the expression levels of antioxidant markers [superoxide dismutase, (SOD), catalase (CAT), glutathione peroxidase (GPx), and glutathione (GSH)], inflammatory cytokines [tumor necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β)], apoptosis-related genes (Bax, Bcl-2, and Caspase-3), matrix remodeling genes [matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), and metallopeptidase inhibitor 1 (TIMP-1)], and bone metabolism regulators [receptor activator of nuclear factor kappa-Β ligand (RANKL) and osteoprotegerin (OPG)]. Oxidative stress and inflammatory measurements were also confirmed via ELISA assays. Results: The results demonstrated that orthodontic force application increased oxidative stress, inflammation, and apoptosis compared to the Control group, disrupted extracellular matrix homeostasis, and increased bone resorption, while LEV administration (LEV + Force) markedly mitigated these abnormalities. In other words, LEV administration increased levels of antioxidant markers, decreased levels of inflammatory cytokines and pro-apoptotic genes, restored extracellular matrix balance (decrease in MMP-2 and MMP-9 with concurrent upregulation of TIMP-1), and limited tissue destruction (decrease in RANKL along with elevation in OPG). In contrast to LEV, VPA did not correct these molecular alterations induced by orthodontic force and, in several parameters, further exacerbated them. Conclusions: In conclusion, molecular data from the animal model indicate that LEV plays a protective role against orthodontic force by reducing excess levels of oxidative stress, apoptosis, and inflammation and homeostatic pathways.

## Linked entities

- **Genes:** SOD1 (superoxide dismutase 1) [NCBI Gene 6647], CAT (catalase) [NCBI Gene 847], GPX (probable phospholipid hydroperoxide glutathione peroxidase) [NCBI Gene 103970350], LOC23687505 (pyrimidodiazepine synthase) [NCBI Gene 23687505], TNF (tumor necrosis factor) [NCBI Gene 7124], IL1B (interleukin 1 beta) [NCBI Gene 3553], BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596], Casp3 (caspase 3) [NCBI Gene 12367], MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313], MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318], TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076], TNFSF11 (TNF superfamily member 11) [NCBI Gene 8600], BTF3P11 (basic transcription factor 3 pseudogene 11) [NCBI Gene 690]
- **Chemicals:** valproic acid (PubChem CID 3121), levetiracetam (PubChem CID 5284583)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** Bax (BCL2 associated X, apoptosis regulator) [NCBI Gene 24887], Mmp9 (matrix metallopeptidase 9) [NCBI Gene 81687], Tnfrsf11b (TNF receptor superfamily member 11B) [NCBI Gene 25341] {aka Opg}, Mmp2 (matrix metallopeptidase 2) [NCBI Gene 81686], Cat (catalase) [NCBI Gene 24248] {aka CS1, Cas1, Cat01, Catl, Cs-1}, Bcl2 (BCL2, apoptosis regulator) [NCBI Gene 24224] {aka Bcl-2}, Il1b (interleukin 1 beta) [NCBI Gene 24494] {aka IL-1F2}, Timp1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 116510] {aka TIMP-1, Timp}, Casp3 (caspase 3) [NCBI Gene 25402] {aka CPP32-beta, Lice, Yama}, Tnfsf11 (TNF superfamily member 11) [NCBI Gene 117516] {aka ODF, OPGL, RANKL, TRANCE}, Tnf (tumor necrosis factor) [NCBI Gene 24835] {aka RATTNF, TNF-alpha, Tnfa}
- **Diseases:** inflammation (MESH:D007249)
- **Chemicals:** LEV (MESH:D000077287), GSH (MESH:D005978), VPA (MESH:D014635)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12843896/full.md

---
Source: https://tomesphere.com/paper/PMC12843896